Here are the 424B prospectus supplements from Turn Therapeutics Inc. (TTRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TTRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TTRX filings page.
Turn Therapeutics Inc. may offer and sell common stock with an aggregate offering price of up to $50,000,000 from time to time through TD Cowen as sales agent or principal, including in at-the-market transactions. Net proceeds, if any, are intended for general corporate purposes, including research and development, preclinical and clinical development, working capital and capital expenditures. TD Cowen may receive up to 3.0% of gross proceeds from each sale.
The company had 30,532,704 shares outstanding as of September 30, 2026. Its dilution illustration assumes a $50,000,000 sale at $9.48 per share and estimates immediate dilution of $8.13 per share for purchasers; $9.48 was the November 6, 2026 closing price, and actual sales prices and share counts may vary.
GX-03, the lead investigational topical candidate for atopic dermatitis, completed Phase 2a in June 2026, with 50 subjects completing and 53 randomized. Week 4 vIGA-AD success was 59.3% for GX-03 (n=27) versus 30.4% for vehicle (n=23); no serious adverse events or treatment-related discontinuations occurred. Phase 2b is planned for 120–136 patients, with topline results expected in the first quarter of 2027; a Phase 2a study for hidradenitis suppurativa is also planned for that quarter.
Turn Therapeutics Inc. (TTRX) registered for resale by selling stockholders up to 25,362,950 shares of common stock, including up to 6,621,190 shares offered by GEM. Turn is not selling shares in this resale and receives none of its proceeds; the selling stockholders receive resale proceeds. GEM's portion includes 5,023,231 shares that may be issued through drawdowns and are registered for resale.
Separately, under the GEM Purchase Agreement, Turn may sell shares to GEM at its discretion through drawdown notices, subject to specified conditions, for up to $85.0 million in aggregate gross proceeds after the prospectus date. Turn estimates up to $84.95 million net over approximately 36 months if it sells shares for the full gross amount; it intends to use proceeds for working capital and general corporate purposes. The registered resale represents approximately 82.96% of the 30,572,704 common shares outstanding as of November 6, 2026. Turn warns that sales, or expectations of sales, could significantly reduce its share price.
The ongoing Phase 2b atopic dermatitis study is intended to enroll 120–136 patients, with topline results expected in the first quarter of 2027. In Phase 2a, 50 subjects completed the trial, with no serious adverse events or treatment-related discontinuations.